Neogen Corporation

NEOG · NasdaqGS · Stock · Healthcare
$12.13
+3.41% today
Delayed price,

What Neogen does

Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$2.65B
P/E (ttm)
—
Forward P/E
30.1
Dividend yield
0.00%
Beta
1.79
Profit margin
-6.3%
Employees
2,636
Headquarters
Lansing, MI, United States
Exchange
NasdaqGS

Performance

1 Month
-6.7%
3 Months
+18.1%
6 Months
+27.5%
1 Year
+106.3%
5 Years
-69.8%
$5.3752-week range$14.26
Biggest setback — last 12 months
-27.7%
16 Feb 2026 → 11 May 2026
Fell from $11.33 to $8.19 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+140.6%
17 Nov 2025 → 21 Sept 2026
Ran from $5.72 to $13.76 — its strongest sustained advance this year.

Price outlook — trend & volatility model

● Trend: Above long-term trend
Price sits above its 200-day average, but the shorter-term averages are not cleanly aligned above/below it.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$10.31 (-15.0%)$12.13$14.27 (+17.6%)
3 Months$9.16 (-24.5%)$12.13$16.07 (+32.5%)
6 Months$8.15 (-32.8%)$12.13$18.05 (+48.8%)
12 Months$6.91 (-43.0%)$12.13$21.29 (+75.5%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 56.3%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 505 shares at $11.95 — Nassif Mikheal, CEO · 2026-10-09
Acquired 9,804 shares at $12.24 — Woteki Catherine E, Director · 2026-10-02
Acquired 9,804 shares at $12.24 — Wainer Andrea F, Director · 2026-10-02
Acquired 9,804 shares at $12.24 — RODRIGUEZ RAFAEL A, Director · 2026-10-02
Acquired 9,804 shares at $12.24 — Pelossof Avi, Director · 2026-10-02
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.